title: Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.
abstract: Intravenous immunoglobulin (IVIg) products are derived from pooled human plasma from thousands of donors and have been used for the treatment of primary immunodeficiency disorders for more than 30 years. IVIg products are also effective in the treatment of autoimmune and inflammatory disorders, however, the precise mechanism(s) of action are not known. Recent data suggest that IVIg has a much broader ability to regulate cellular immunity, including innate and adaptive components. IVIg-induced upregulation of Fcγ receptor IIB on B cells appears to be an important mode of action in suppression of antigen-presenting cell activity and antibody production. IVIg is also a recently recognized modifier of complement activation and injury. Analysis of clinical studies examining the use of IVIg in desensitization protocols and for treatment of antibody-mediated rejection in transplant recipients are supportive. Here, we discuss these important advancements and their relevance to transplant medicine.
authors: Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. sjordan@cshs.org
authors: Stanley C
authors: SC
authors: Jordan
authors: Mieko
authors: M
authors: Toyoda
authors: Ashley A
authors: AA
authors: Vo